Summary
Johnson & Johnson (JNJ) filed an 8-K on January 23, 2018, reporting its financial results for the fourth quarter and full year ended December 31, 2017. The filing primarily consists of a press release and supplementary sales data, providing investors with key financial performance metrics. This information is crucial for assessing the company's operational health, revenue generation, and profitability across its diverse business segments, including Pharmaceuticals, Medical Devices, and Consumer Health.
Key Highlights
- 1Johnson & Johnson announced its Q4 and full-year 2017 financial results on January 23, 2018.
- 2The 8-K filing includes the official press release detailing sales and earnings for the periods ended December 31, 2017.
- 3Investors can find unaudited comparative supplementary sales data and condensed consolidated statements of earnings within the filing.
- 4The reporting covers both the fourth quarter and the entirety of the fiscal year 2017.
- 5This report provides essential financial performance information for evaluating JNJ's operational and financial condition.
Frequently Asked Questions
The main purpose of this 8-K filing is to officially announce and disseminate Johnson & Johnson's sales and earnings results for the fourth quarter and the full fiscal year 2017, which concluded on December 31, 2017.
The detailed financial results are primarily contained within the attached press release (Exhibit 99.15) and the unaudited comparative supplementary sales data and condensed consolidated statements of earnings (Exhibit 99.20) included with the 8-K filing.
The financial results reported in this 8-K cover the fourth quarter of 2017 and the full fiscal year 2017, both ending on December 31, 2017.
The filing indicates that the comparative supplementary sales data and condensed consolidated statements of earnings are 'Unaudited'.